1
|
Lepareur N, Ramée B, Mougin-Degraef M, Bourgeois M. Clinical Advances and Perspectives in Targeted Radionuclide Therapy. Pharmaceutics 2023; 15:1733. [PMID: 37376181 DOI: 10.3390/pharmaceutics15061733] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2023] [Revised: 06/09/2023] [Accepted: 06/13/2023] [Indexed: 06/29/2023] Open
Abstract
Targeted radionuclide therapy has become increasingly prominent as a nuclear medicine subspecialty. For many decades, treatment with radionuclides has been mainly restricted to the use of iodine-131 in thyroid disorders. Currently, radiopharmaceuticals, consisting of a radionuclide coupled to a vector that binds to a desired biological target with high specificity, are being developed. The objective is to be as selective as possible at the tumor level, while limiting the dose received at the healthy tissue level. In recent years, a better understanding of molecular mechanisms of cancer, as well as the appearance of innovative targeting agents (antibodies, peptides, and small molecules) and the availability of new radioisotopes, have enabled considerable advances in the field of vectorized internal radiotherapy with a better therapeutic efficacy, radiation safety and personalized treatments. For instance, targeting the tumor microenvironment, instead of the cancer cells, now appears particularly attractive. Several radiopharmaceuticals for therapeutic targeting have shown clinical value in several types of tumors and have been or will soon be approved and authorized for clinical use. Following their clinical and commercial success, research in that domain is particularly growing, with the clinical pipeline appearing as a promising target. This review aims to provide an overview of current research on targeting radionuclide therapy.
Collapse
Affiliation(s)
- Nicolas Lepareur
- Comprehensive Cancer Center Eugène Marquis, 35000 Rennes, France
- Inserm, INRAE, Institut NUMECAN (Nutrition, Métabolismes et Cancer)-UMR 1317, Univ Rennes, 35000 Rennes, France
| | - Barthélémy Ramée
- Nuclear Medicine Department, Nantes University Hospital, 44000 Nantes, France
| | - Marie Mougin-Degraef
- Nuclear Medicine Department, Nantes University Hospital, 44000 Nantes, France
- Inserm, CNRS, CRCI2NA (Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes-Angers)-UMR 1307, Université de Nantes, ERL 6001, 44000 Nantes, France
| | - Mickaël Bourgeois
- Nuclear Medicine Department, Nantes University Hospital, 44000 Nantes, France
- Inserm, CNRS, CRCI2NA (Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes-Angers)-UMR 1307, Université de Nantes, ERL 6001, 44000 Nantes, France
- Groupement d'Intérêt Public ARRONAX, 1 Rue Aronnax, 44817 Saint Herblain, France
| |
Collapse
|
2
|
Grémy O, Mougin-Degraef M, Devilliers K, Berdal M, Laroche P, Miccoli L. DTPA-Coated Liposomes as a New Delivery Vehicle for Plutonium Decorporation. Radiat Res 2021; 195:77-92. [PMID: 33180911 DOI: 10.1667/rade-20-00142.1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2020] [Accepted: 10/05/2020] [Indexed: 11/03/2022]
Abstract
Administration of diethylenetriaminepentaacetic acid (DTPA) is the treatment approach used to promote the decorporation of internalized plutonium. Here we evaluated the efficacy of PEGylated liposomes coated with DTPA, primarily designed to prevent enhanced plutonium accumulation in bones, compared to marketed nonliposomal DTPA and liposomes encapsulating DTPA. The comparative effects were examined in terms of reduction of activity in tissues of plutonium-injected rats. The prompt treatment with DTPA-coated liposomes elicited an even greater efficacy than that with liposome-encapsulated DTPA in limiting skeletal plutonium. This advantage, undoubtedly due to the anchorage of DTPA to the outer layer of liposomes, is discussed, as well as the reason for the loss of this superiority at delayed times after contamination. Plutonium complexed with DTPA-coated liposomes in extracellular compartments was partly diverted into the liver and the spleen. These complexes and those directly formed inside hepatic and splenic cells appeared to be degraded, then released from cells at extremely slow rates. This transitory accumulation of activity, which could not be counteracted by combining both liposomal forms, entailed an underestimation of the efficacy of DTPA-coated liposomes on soft tissue plutonium until total elimination probably more than one month after treatment. DTPA-coated liposomes may provide the best delivery vehicle of DTPA for preventing plutonium deposition in tissues, especially in bone where nuclides become nearly impossible to remove once fixed. Additional development efforts are needed to limit the diversion or to accelerate cell release of plutonium bound to DTPA-coated liposomes, using a labile bond for DTPA attachment.
Collapse
Affiliation(s)
- Olivier Grémy
- Laboratoire de RadioToxicologie, CEA, Université de Paris-Saclay, Bruyères-le-Châtel, France
| | - Marie Mougin-Degraef
- CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France.,Nuclear Medicine, University Hospital, Nantes, France
| | - Karine Devilliers
- Laboratoire de RadioToxicologie, CEA, Université de Paris-Saclay, Bruyères-le-Châtel, France
| | - Marion Berdal
- Nuclear Medicine, University Hospital, Nantes, France
| | - Pierre Laroche
- Direction of Health, Security, Environment and Radioprotection, ORANO, Paris, France
| | - Laurent Miccoli
- Laboratoire de RadioToxicologie, CEA, Université de Paris-Saclay, Bruyères-le-Châtel, France
| |
Collapse
|
3
|
Perrin J, Capitao M, Mougin-Degraef M, Guérard F, Faivre-Chauvet A, Rbah-Vidal L, Gaschet J, Guilloux Y, Kraeber-Bodéré F, Chérel M, Barbet J. Cell Tracking in Cancer Immunotherapy. Front Med (Lausanne) 2020; 7:34. [PMID: 32118018 PMCID: PMC7033605 DOI: 10.3389/fmed.2020.00034] [Citation(s) in RCA: 43] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2019] [Accepted: 01/23/2020] [Indexed: 12/19/2022] Open
Abstract
The impressive development of cancer immunotherapy in the last few years originates from a more precise understanding of control mechanisms in the immune system leading to the discovery of new targets and new therapeutic tools. Since different stages of disease progression elicit different local and systemic inflammatory responses, the ability to longitudinally interrogate the migration and expansion of immune cells throughout the whole body will greatly facilitate disease characterization and guide selection of appropriate treatment regiments. While using radiolabeled white blood cells to detect inflammatory lesions has been a classical nuclear medicine technique for years, new non-invasive methods for monitoring the distribution and migration of biologically active cells in living organisms have emerged. They are designed to improve detection sensitivity and allow for a better preservation of cell activity and integrity. These methods include the monitoring of therapeutic cells but also of all cells related to a specific disease or therapeutic approach. Labeling of therapeutic cells for imaging may be performed in vitro, with some limitations on sensitivity and duration of observation. Alternatively, in vivo cell tracking may be performed by genetically engineering cells or mice so that may be revealed through imaging. In addition, SPECT or PET imaging based on monoclonal antibodies has been used to detect tumors in the human body for years. They may be used to detect and quantify the presence of specific cells within cancer lesions. These methods have been the object of several recent reviews that have concentrated on technical aspects, stressing the differences between direct and indirect labeling. They are briefly described here by distinguishing ex vivo (labeling cells with paramagnetic, radioactive, or fluorescent tracers) and in vivo (in vivo capture of injected radioactive, fluorescent or luminescent tracers, or by using labeled antibodies, ligands, or pre-targeted clickable substrates) imaging methods. This review focuses on cell tracking in specific therapeutic applications, namely cell therapy, and particularly CAR (Chimeric Antigen Receptor) T-cell therapy, which is a fast-growing research field with various therapeutic indications. The potential impact of imaging on the progress of these new therapeutic modalities is discussed.
Collapse
Affiliation(s)
- Justine Perrin
- CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France
| | - Marisa Capitao
- CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France
| | - Marie Mougin-Degraef
- CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France.,Nuclear Medicine, University Hospital, Nantes, France
| | - François Guérard
- CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France
| | - Alain Faivre-Chauvet
- CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France.,Nuclear Medicine, University Hospital, Nantes, France
| | - Latifa Rbah-Vidal
- CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France
| | - Joëlle Gaschet
- CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France
| | - Yannick Guilloux
- CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France
| | - Françoise Kraeber-Bodéré
- CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France.,Nuclear Medicine, University Hospital, Nantes, France.,Nuclear Medicine, ICO Cancer Center, Saint-Herblain, France
| | - Michel Chérel
- CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France.,Nuclear Medicine, ICO Cancer Center, Saint-Herblain, France
| | | |
Collapse
|
4
|
Grémy O, Miccoli L, Lelan F, Bohand S, Mougin-Degraef M. Liposomal DTPA as a good strategy for enhancing Pu decorporation regardless of treatment regimen. BIO Web Conf 2019. [DOI: 10.1051/bioconf/20191406002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
5
|
Huclier-Markai S, Alliot C, Kerdjoudj R, Mougin-Degraef M, Chouin N, Haddad F. Promising Scandium Radionuclides for Nuclear Medicine: A Review on the Production and Chemistry up to In Vivo Proofs of Concept. Cancer Biother Radiopharm 2018; 33:316-329. [PMID: 30265573 DOI: 10.1089/cbr.2018.2485] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Scandium radionuclides have been identified in the late 1990s as promising for nuclear medicine applications, but have been set aside for about 20 years. Among the different isotopes of scandium, 43Sc and 44Sc are interesting for positron emission tomography imaging, whereas 47Sc is interesting for therapy. The 44Sc/47Sc or 43Sc/47Sc pairs could be thus envisaged as true theranostic pairs. Another interesting aspect of scandium is that its chemistry is governed by the trivalent ion, Sc3+. When combined with its hardness and its size, it gives this element a lanthanide-like behavior. It is then also possible to use it in a theranostic approach in combination with 177Lu or other lanthanides. This article aims to review the progresses that have been made over the last decade on scandium isotope production and coordination chemistry. It also reviews the radiolabeling aspects and the first (pre) clinical studies performed.
Collapse
Affiliation(s)
- Sandrine Huclier-Markai
- 1 Laboratoire Subatech , UMR 6457, IMT Nantes Atlantique/CNRS-IN2P3/Université de Nantes, Nantes Cedex, France .,2 ARRONAX GIP , Nantes Cedex, France
| | - Cyrille Alliot
- 2 ARRONAX GIP , Nantes Cedex, France .,3 CRCINA, Inserm/CNRS/Université de Nantes , Nantes Cedex, France
| | - Rabha Kerdjoudj
- 1 Laboratoire Subatech , UMR 6457, IMT Nantes Atlantique/CNRS-IN2P3/Université de Nantes, Nantes Cedex, France .,2 ARRONAX GIP , Nantes Cedex, France
| | | | - Nicolas Chouin
- 3 CRCINA, Inserm/CNRS/Université de Nantes , Nantes Cedex, France .,4 Unité AMaROC ONIRIS Site de la Chantrerie , Nantes Cedex, France
| | - Ferid Haddad
- 1 Laboratoire Subatech , UMR 6457, IMT Nantes Atlantique/CNRS-IN2P3/Université de Nantes, Nantes Cedex, France .,2 ARRONAX GIP , Nantes Cedex, France
| |
Collapse
|
6
|
Huclier-Markai S, Grivaud-Le Du A, N'tsiba E, Montavon G, Mougin-Degraef M, Barbet J. Coupling a gamma-ray detector with asymmetrical flow field flow fractionation (AF4): Application to a drug-delivery system for alpha-therapy. J Chromatogr A 2018; 1573:107-114. [PMID: 30224278 DOI: 10.1016/j.chroma.2018.08.065] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2018] [Revised: 08/21/2018] [Accepted: 08/31/2018] [Indexed: 11/26/2022]
Abstract
Alpha-particle-emitting radionuclides have been the subject of considerable investigation as cancer therapeutics, since they have the advantages of high potency and specificity. Among α-emitting radionuclides that are medically relevant and currently available, the lead-212/bismuth-212 radionuclide pair could constitute an in vivo generator. Considering its short half-life (T1/2 = 60.6 min), 212Bi can only be delivered using labelled carrier molecules that would rapidly accumulate in the target tumor. To expand the range of applications, an interesting method is to use its longer half-life parent 212Pb (T1/2 = 10.6 h) that decays to 212Bi. The challenge consists in keeping 212Bi bound to the vector after the 212Pb decay. Preclinical and clinical studies have shown that a variety of vectors may be used to target alpha-emitting radionuclides to cancer cells. Nanoparticles, notably liposomes, allow combined targeting options, achieving high specific activities, easier combination of imaging and therapy and development of multimodality therapeutic agents (e.g., radionuclide therapy plus chemotherapy). The aim of this work consists in assessing the in vitro stability of 212Pb/212Bi encapsulation in the liposomes. Indeed, the release of the radionuclide from the carrier molecules might causes toxicity to normal tissues. To reach this goal, Asymmetrical Flow Field-Flow Fractionation (AF4) coupled with a Multi-Angle Light Scattering detector (MALS) was used and coupling with a gamma (γ) ray detector was developed. AF4-MALS-γ was shown to be a powerful tool for monitoring the liposome size together with the incorporation of the high energy alpha emitter. This was successfully extended to assess the stability of 212Bi-radiolabelled liposomes in serum showing that more than 85% of 212Pb/212Bi is retained after 24 h of incubation at 37 °C.
Collapse
Affiliation(s)
- Sandrine Huclier-Markai
- SUBATECH, UMR 6457, IMT Atlantique CNRS/IN2P3-Université de Nantes-, 4 rue Alfred Kastler La Chantrerie, BP 20722, 44307 Nantes Cedex 3, France; GIP ARRONAX, 1 Rue Aronnax, CS 10112, 44817 Saint-Herblain Cedex, France.
| | - Alicia Grivaud-Le Du
- SUBATECH, UMR 6457, IMT Atlantique CNRS/IN2P3-Université de Nantes-, 4 rue Alfred Kastler La Chantrerie, BP 20722, 44307 Nantes Cedex 3, France
| | - Estelle N'tsiba
- SUBATECH, UMR 6457, IMT Atlantique CNRS/IN2P3-Université de Nantes-, 4 rue Alfred Kastler La Chantrerie, BP 20722, 44307 Nantes Cedex 3, France; GIP ARRONAX, 1 Rue Aronnax, CS 10112, 44817 Saint-Herblain Cedex, France
| | - Gilles Montavon
- SUBATECH, UMR 6457, IMT Atlantique CNRS/IN2P3-Université de Nantes-, 4 rue Alfred Kastler La Chantrerie, BP 20722, 44307 Nantes Cedex 3, France
| | - Marie Mougin-Degraef
- Centre de Recherche en Cancérologie et Immunologie de Nantes-Angers CRCINA, Inserm UMR 1232, Université de Nantes, Institut de Recherche en Santé de l'Université de Nantes, 8 quai Moncousu, BP70721, 44007 Nantes Cedex 1, France
| | - Jacques Barbet
- GIP ARRONAX, 1 Rue Aronnax, CS 10112, 44817 Saint-Herblain Cedex, France; Centre de Recherche en Cancérologie et Immunologie de Nantes-Angers CRCINA, Inserm UMR 1232, Université de Nantes, Institut de Recherche en Santé de l'Université de Nantes, 8 quai Moncousu, BP70721, 44007 Nantes Cedex 1, France
| |
Collapse
|
7
|
Grémy O, Miccoli L, Lelan F, Bohand S, Cherel M, Mougin-Degraef M. Delivery of DTPA through Liposomes as a Good Strategy for Enhancing Plutonium Decorporation Regardless of Treatment Regimen. Radiat Res 2018. [DOI: 10.1667/rr14968.1] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Affiliation(s)
- Olivier Grémy
- Laboratoire de RadioToxicologie, CEA, Université de Paris-Saclay, Bruyères le Châtel, France
| | - Laurent Miccoli
- Laboratoire de RadioToxicologie, CEA, Université de Paris-Saclay, Bruyères le Châtel, France
| | - Faustine Lelan
- Laboratoire de RadioToxicologie, CEA, Université de Paris-Saclay, Bruyères le Châtel, France
| | | | - Michel Cherel
- CRCINA, Inserm, CNRS, Université d'Angers, Université de Nantes, Nantes, France
| | | |
Collapse
|
8
|
Rauscher A, Frindel M, Rajerison H, Gouard S, Maurel C, Barbet J, Faivre-Chauvet A, Mougin-Degraef M. Improvement of the Targeting of Radiolabeled and Functionalized Liposomes with a Two-Step System Using a Bispecific Monoclonal Antibody (Anti-CEA × Anti-DTPA-In). Front Med (Lausanne) 2015; 2:83. [PMID: 26636087 PMCID: PMC4658472 DOI: 10.3389/fmed.2015.00083] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2015] [Accepted: 11/06/2015] [Indexed: 01/16/2023] Open
Abstract
This study proposes liposomes as a new tool for pretargeted radioimmunotherapy (RIT) in solid tumors. Tumor pretargeting is obtained by using a bispecific monoclonal antibody [BsmAb, anti-CEA × anti-DTPA-indium complex (DTPA–In)] and pegylated radioactive liposomes containing a lipid-hapten conjugate (DSPE–PEG–DTPA–In). In this work, the immunospecificity of tumor targeting is demonstrated both in vitro by fluorescence microscopy and in vivo by biodistribution studies.
Collapse
Affiliation(s)
- Aurore Rauscher
- Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), 6299 CNRS, UMR 892 - INSERM, Université de Nantes , Nantes , France ; Nuclear Medicine Department, Institut de Cancérologie de l'Ouest , Saint Herblain , France
| | - Mathieu Frindel
- Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), 6299 CNRS, UMR 892 - INSERM, Université de Nantes , Nantes , France ; Nuclear Medicine Department, University Hospital Nantes , Nantes , France
| | - Holisoa Rajerison
- Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), 6299 CNRS, UMR 892 - INSERM, Université de Nantes , Nantes , France
| | - Sébastien Gouard
- Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), 6299 CNRS, UMR 892 - INSERM, Université de Nantes , Nantes , France
| | - Catherine Maurel
- Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), 6299 CNRS, UMR 892 - INSERM, Université de Nantes , Nantes , France
| | - Jacques Barbet
- Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), 6299 CNRS, UMR 892 - INSERM, Université de Nantes , Nantes , France ; GIP Arronax , Saint Herblain , France
| | - Alain Faivre-Chauvet
- Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), 6299 CNRS, UMR 892 - INSERM, Université de Nantes , Nantes , France ; Nuclear Medicine Department, University Hospital Nantes , Nantes , France
| | - Marie Mougin-Degraef
- Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), 6299 CNRS, UMR 892 - INSERM, Université de Nantes , Nantes , France ; Nuclear Medicine Department, University Hospital Nantes , Nantes , France
| |
Collapse
|
9
|
Rauscher A, Frindel M, Maurel C, Maillasson M, Le Saëc P, Rajerison H, Gestin JF, Barbet J, Faivre-Chauvet A, Mougin-Degraef M. Influence of pegylation and hapten location at the surface of radiolabelled liposomes on tumour immunotargeting using bispecific antibody. Nucl Med Biol 2014; 41 Suppl:e66-74. [DOI: 10.1016/j.nucmedbio.2013.12.012] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2013] [Revised: 12/05/2013] [Accepted: 12/18/2013] [Indexed: 11/25/2022]
|
10
|
Rajerison H, Guérard F, Mougin-Degraef M, Bourgeois M, Da Silva I, Chérel M, Barbet J, Faivre-Chauvet A, Gestin JF. Radioiodinated and astatinated NHC rhodium complexes: synthesis. Nucl Med Biol 2013; 41 Suppl:e23-9. [PMID: 24661351 DOI: 10.1016/j.nucmedbio.2013.12.004] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2013] [Revised: 12/04/2013] [Accepted: 12/04/2013] [Indexed: 01/01/2023]
Abstract
INTRODUCTION The clinical development of radioimmunotherapy with astatine-211 is limited by the lack of a stable radiolabeling method for antibody fragments. An astatinated N-heterocyclic carbene (NHC) Rhodium complex was assessed for the improvement of radiolabeling methodologies with astatine. METHODS Wet harvested astatine-211 in diisopropyl ether was used. Astatine was first reduced with cysteine then was reacted with a chlorinated Rh-NHC precursor to allow the formation of the astatinated analogue. Reaction conditions have been optimized. Astatine and iodine reactivity were also compared. Serum stability of the astatinated complex has been evaluated. RESULTS Quantitative formation of astatide was observed when cysteine amounts higher than 46.2 nmol/μl of astatine solution were added. Nucleophilic substitution kinetics showed that high radiolabeling yields were obtained within 15 min at 60°C (88%) or within 5 min at 100°C (95%). Chromatographic characteristics of this new astatinated compound have been correlated with the cold iodinated analog ones. The radioiodinated complex was also synthesized from the same precursor (5 min. at 100°C, up to 85%) using [(125)I]NaI as a radiotracer. In vitro stability of the astatinated complex was controlled after 15 h incubation in human serum at 4°C and 37°C. No degradation was observed, indicating the good chemical and enzymatic stability. CONCLUSION The astatinated complex was obtained in good yield and exhibited good chemical and enzymatic stability. These preliminary results demonstrate the interest of this new radiolabeling methodology, and further functionalizations should open new possibilities in astatine chemistry. ADVANCES IN KNOWLEDGE AND IMPLICATIONS FOR PATIENT CARE Although there are many steps and pitfalls before clinical use for a new prosthetic group from the family of NHC complexes, this work may open a new path for astatine-211 targeting.
Collapse
Affiliation(s)
- Holisoa Rajerison
- Centre de Recherche en Cancérologie Nantes/Angers, 44007 Nantes Cedex 1, France.
| | - François Guérard
- Centre de Recherche en Cancérologie Nantes/Angers, 44007 Nantes Cedex 1, France
| | | | - Mickael Bourgeois
- Centre de Recherche en Cancérologie Nantes/Angers, 44007 Nantes Cedex 1, France; GIP ARRONAX, 44817 Saint-Herblain Cedex, France
| | | | - Michel Chérel
- Centre de Recherche en Cancérologie Nantes/Angers, 44007 Nantes Cedex 1, France
| | - Jacques Barbet
- Centre de Recherche en Cancérologie Nantes/Angers, 44007 Nantes Cedex 1, France; GIP ARRONAX, 44817 Saint-Herblain Cedex, France
| | | | - Jean-François Gestin
- Centre de Recherche en Cancérologie Nantes/Angers, 44007 Nantes Cedex 1, France.
| |
Collapse
|
11
|
Bourgeois M, Rajerison H, Guerard F, Mougin-Degraef M, Barbet J, Michel N, Cherel M, Faivre-Chauvet A. Contribution of [64Cu]-ATSM PET in molecular imaging of tumour hypoxia compared to classical [18F]-MISO--a selected review. Nucl Med Rev Cent East Eur 2012; 14:90-5. [PMID: 22219149 DOI: 10.5603/nmr.2011.00022] [Citation(s) in RCA: 55] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
During the carcinogenesis process, tumour cells often have a more rapid proliferation potential than cells that participate in blood capillary formation by neoangiogenesis. As a consequence of the poorly organized vasculature of various solid tumours, a limited oxygen delivery is observed. This hypoxic mechanism frequently occurs in solid cancers and can lead to therapeutic resistance. The present selected literature review is focused on the comparison of two positron emitting radiopharmaceuticals agents, which are currently leaders in tumour hypoxia imaging by PET. {18F}-fluoromisonidazole (=FMISO) is most commonly used as an investigational PET agent with an investigational new drug exemption from the FDA, while {64Cu}-diacetyl-bis(N4-methylthiosemicarbazone) (64Cu-ATSM) has been presented as an alternative radiopharmaceutical not yet readily available. The comparison of these two radiopharmaceutical agents is particularly focused on isotope properties, radiopharmaceutical labelling process, pharmacological mechanisms, dosimetry data in patients, and clinical results in terms of image contrast. PET imaging has demonstrated a good efficacy in tumour hypoxia imaging with both FMISO and Cu-ATSM, but FMISO has presented too slow an in vivo accumulation and a weak image contrast of the hypoxia area. Despite a less favourable dosimetry, 64Cu-ATSM appears superior in terms of imaging performance, calling for industrial and clinical development of this innovative radiopharmaceutical.
Collapse
Affiliation(s)
- Mickaël Bourgeois
- Centre de Recherche en Cancérologie Nantes-Angers, IRT-UN 8 quai Moncousu, 44007 Nantes cedex 1, France.
| | | | | | | | | | | | | | | |
Collapse
|
12
|
Le Du A, Mougin-Degraef M, Botosoa E, Rauscher A, Faivre Chauvet A, Barbet J, Montavon G. In vivo
212Pb/212Bi generator using indium-DTPA-tagged liposomes. RADIOCHIM ACTA 2011. [DOI: 10.1524/ract.2011.1871] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Abstract
Indium-DTPA-tagged liposomes were studied in the present work as carriers of in vivo
212Pb/ 212Bi generator to be used in targeted alpha therapy. The liposomal uptake of 212Pb, into preformed liposomes, was investigated using different lipophilic chelate (DCP, 2,3-dimercapto-1-propanol (BAL), sodium acetate, and A23187), as a function of various parameters (temperature, concentrations of lipids, Pb, DTPA, ...) with 212Pb as a tracer. Different formulations of liposomes were tested to evaluate the radiolabeling efficiency. No complexing agent was necessary for the passage of Pb2+ through the membrane. It occurs naturally via a partial permeability of the lipid bilayer, which increases with the temperature. A complexing agent (DTPA) appears necessary to concentrate Pb in the internal compartment of the liposomes. Conditions were found (T=65 ºC, internal DTPA concentration of 0.025 M, pH 7.4, ...) yielding a high and rapid uptake of 212Pb in liposomes. The protocol established provides a novel method for the efficient entrapment of about 2–3 Pb atoms per liposome with a yield of 75% in conditions relevant for nuclear medicine.
Collapse
Affiliation(s)
- A. Le Du
- École des mines de Nantes, SUBATECH, UMR 6457, Nantes Cedex 3, Frankreich
| | - M. Mougin-Degraef
- Université de Nantes, Centre de Recherche en Cancérologie, Nantes Cedex 1, Frankreich
| | - E. Botosoa
- Université de Nantes, Centre de Recherche en Cancérologie, Nantes Cedex 1, Frankreich
| | | | - A. Faivre Chauvet
- Université de Nantes, Centre de Recherche en Cancérologie, Nantes Cedex 1, Frankreich
| | - Jacques Barbet
- Département de Recherche en Cancérologie, Inserm, U892, Nantes cedex 1, Frankreich
| | | |
Collapse
|
13
|
Mougin-Degraef M, Jestin E, Bruel D, Remaud-Le Saëc P, Morandeau L, Faivre-Chauvet A, Barbet J. High-Activity Radio-Iodine Labeling of Conventional and Stealth Liposomes. J Liposome Res 2008; 16:91-102. [PMID: 16556552 DOI: 10.1080/08982100500528941] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
A new method to label preformed liposomes with high activities of radiohalogenated compounds has been developed. It uses activated esters of simple synthetic molecules that may be readily halogenated, such as Bolton-Hunter reagent (BH), and arginine-containing liposomes. BH, in the form of an activated ester, crosses the liposome membrane to react with arginine inside the liposomes, as demonstrated by thin-layer chromatography and by the fact that saline-containing liposomes, or hydrolyzed BH or the water soluble sulfo-BH afforded only marginal encapsulation yields. Under optimized conditions, between 37 and 55 degrees C, 62 +/- 4% (mean +/- SD) of radiolabeled BH were consistently encapsulated in the liposomes within 30 min. In molar amounts, this corresponds to a mean of 56 nmol of BH per micromol of lipids. Based on achievable specific activity, up to 2.8 GBq of iodine-131 could be entrapped per micromol of lipids. Leakage of radioactivity was very low, with less than 5% of the encapsulated activity released within 6 days at 4 degrees C in phosphate-buffered saline and less than 50% within 24 h in human serum at 37 degrees C. The labeling stability, and the fact that both conventional and PEGylated liposomes can be readily labeled with high doses of radioactivity, will make this technique useful for in vivo targeting applications, such as tumor detection (using iodine-123 or iodine-124) or therapy (with iodine-131 or astatine-211).
Collapse
|
14
|
Bourgeois M, Guerard F, Alliot C, Mougin-Degraef M, Rajérison H, Remaud-Le Saëc P, Gestin JF, Davodeau F, Chérel M, Barbet J, Faivre-Chauvet A. Feasibility of the radioastatination of a monoclonal antibody with astatine-211 purified by wet extraction. J Labelled Comp Radiopharm 2008; 51:379-83. [DOI: 10.1002/jlcr.1543] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2008] [Revised: 08/18/2008] [Accepted: 08/19/2008] [Indexed: 11/05/2022]
|
15
|
Mougin-Degraef M, Bourdeau C, Jestin E, Saï-Maurel C, Bourgeois M, Saëc PRL, Thédrez P, Gestin JF, Barbet J, Faivre-Chauvet A. Doubly radiolabeled liposomes for pretargeted radioimmunotherapy. Int J Pharm 2007; 344:110-7. [PMID: 17592745 DOI: 10.1016/j.ijpharm.2007.05.024] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2007] [Revised: 05/10/2007] [Accepted: 05/12/2007] [Indexed: 11/28/2022]
Abstract
The aim of this study was to design liposomes as radioactivity carriers for pretargeted radioimmunotherapy with favorable pharmacokinetic parameters. To monitor the liposomes integrity in vivo, their surface was radiolabeled with indium-111 bound to DTPA-derivatized phosphatidylethanolamine (DSPE-DTPA) and the aqueous phase was labeled by using an original active loading technique of radioiodinated Bolton-Hunter reagent (BH) that reacts with pre-encapsulated arginine to form a positively charged conjugate ((125)I-BH-arginine). Different formulations of doubly radiolabeled liposomes were tested in vitro and in vivo to evaluate radiolabeling stability, integrity of the vesicles and their pharmacokinetics. Radiolabeling yields were high (surface >75%, encapsulation >60%) and stable (>85% after 24 h in serum 37 degrees C). In vivo, the pharmacokinetic behavior of doubly radiolabeled liposomes was strongly dependant on the formulation. Blood clearance of PEGylated liposomes (DSPC/Chol/DSPE-DTPA/DSPE-PEG5%) was 0.15 mL/h compared to a conventional formulation (DSPC/Chol/DSPE-DTPA: clearance 1.44 mL/h). Non-encapsulated BH-arginine conjugate was quickly eliminated in urine (clearance 6.04 mL/h). Blood kinetics of the two radionuclides were similar and radiochromatographic profiles of mice serum confirmed the integrity of circulating liposomes. The significant reduction of activity uptake in organs after liposome catabolism (liver and spleen), achieved by the rapid renal elimination of (125)I-BH-arginine, should bring significant improvements for targeted radionuclide therapy with sterically-stabilized liposomes.
Collapse
Affiliation(s)
- M Mougin-Degraef
- Département de recherche en cancérologie, INSERM, U601, Université de Nantes, 9 quai Moncousu 44093, Nantes Cedex 1, France.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Bourgeois M, Mougin-Degraef M, Leost F, Cherel M, Gestin JF, Le Bars D, Barbet J, Faivre-Chauvet A. Purification of [18F]-fluoro-l-thymidine ([18F]-FLT) for positron emission tomography imaging. J Pharm Biomed Anal 2007; 45:154-157. [PMID: 17566690 DOI: 10.1016/j.jpba.2007.04.034] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2007] [Revised: 04/27/2007] [Accepted: 04/27/2007] [Indexed: 10/23/2022]
Abstract
3'-Deoxy-3'-[18F]fluorothymidine ([18F]-FLT) has recently been described as a positron emission tomography (PET) radiopharmaceutical for visualizing cellular proliferation in vivo. All published radiosyntheses of [18F]-FLT provide crude products that must be purified before injection to human. This study describes a reliable purification procedure for [18F]-FLT. It is based on HPLC. In 17.9+/-0.5 min, pure [18F]-FLT is obtained that could be injected to human after a passage through a sterile 0.22 microm filter.
Collapse
Affiliation(s)
- Mickaël Bourgeois
- Département de Recherche en Cancérologie, Université de Nantes, INSERM, U601, Institut de Biologie, 9 quai Moncousu, 44093 Nantes Cedex 1, France.
| | - Marie Mougin-Degraef
- Département de Recherche en Cancérologie, Université de Nantes, INSERM, U601, Institut de Biologie, 9 quai Moncousu, 44093 Nantes Cedex 1, France
| | - Françoise Leost
- Cancéropôle Grand Ouest, CHU Nantes, Immeuble Deurbroucq, 5 allée de l'île Gloriette, 44093 Nantes Cedex 1, France
| | - Michel Cherel
- Département de Recherche en Cancérologie, Université de Nantes, INSERM, U601, Institut de Biologie, 9 quai Moncousu, 44093 Nantes Cedex 1, France
| | - Jean-François Gestin
- Département de Recherche en Cancérologie, Université de Nantes, INSERM, U601, Institut de Biologie, 9 quai Moncousu, 44093 Nantes Cedex 1, France
| | | | - Jacques Barbet
- Département de Recherche en Cancérologie, Université de Nantes, INSERM, U601, Institut de Biologie, 9 quai Moncousu, 44093 Nantes Cedex 1, France
| | - Alain Faivre-Chauvet
- Département de Recherche en Cancérologie, Université de Nantes, INSERM, U601, Institut de Biologie, 9 quai Moncousu, 44093 Nantes Cedex 1, France
| |
Collapse
|
17
|
Jestin E, Mougin-Degraef M, Faivre-Chauvet A, Remaud-Le Saëc P, Hindre F, Benoit JP, Chatal JF, Barbet J, Gestin JF. Radiolabeling and targeting of lipidic nanocapsules for applications in radioimmunotherapy. Q J Nucl Med Mol Imaging 2007; 51:51-60. [PMID: 17372573] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/14/2023]
Abstract
AIM Radioimmunotherapy is limited in some cases by the low radioactive doses delivered to tumor cells by antibodies or pretargeted haptens. In order to increase this dose, lipidic nanocapsules (LNC) with a hydrophobic core are proposed as radionuclide vectors that could be targeted to cancer cells by a bispecific anti-tumor x anti-hapten antibody after incorporation of different haptens in the nanocapsule membrane. METHODS To bind different radionuclides to the nanocapsules, several bifunctional chelating agents (BCA) were used to form stable complexes with the radionuclides. Some of them are hydrophilic for LNC shell while others are lipophilic to radiolabel the core. Poly(ethylene glycols) (PEG) were used to increase the residence time in blood. Since PEG can modify haptens recognition by the bispecific antibody and radiolabeling efficiency, haptens, BCA or Bolton-Hunter reagent (BH) were attached to the PEG extremity to optimize accessibility. Specific constructs (DSPE-PEG-haptens, DSPE-PEG-BCA, and DSPE-PEG-BH) were synthesized to develop these new radiolabeled vector formulations. Large amounts of PEG have been introduced by a postinsertion method without important change in nanocapsule size and properties. The nanocapsule core was radiolabeled with a lipophilic [(99m)Tc]SSS complex. RESULTS Serum stability studies showed that this (99m)Tc-labeling method was efficient for at least 20 h. Concerning the nanocapsule surface, several methods have been performed for (111)In-labeling by using DSPE-PEG-DTPA and for (125)I-labeling with DSPE-PEG-BH. CONCLUSIONS The nanocapsules labeling feasibility with a variety of radionuclides and their stability were demonstrated in this paper.
Collapse
Affiliation(s)
- E Jestin
- INSERM, U 601, University of Nantes, Nantes, France
| | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Morandeau L, Saec PRL, Ouadi A, Bultel-Rivière K, Mougin-Degraef M, France-Robert AD, Faivre-Chauvet A, Gestin JF. Synthesis and evaluation of a novel samarium-153 bifunctional chelating agent for radioimmunotargeting applications. J Labelled Comp Radiopharm 2006. [DOI: 10.1002/jlcr.1031] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
19
|
Blanc F, Salaun PY, Couturier O, Querellou S, Le Duc-Pennec A, Mougin-Degraef M, Bizais Y, Legendre JM. 99mTc ovalbumin labelled eggs for gastric emptying scintigraphy: in-vitro comparison of solid food markers. Nucl Med Commun 2005; 26:1021-5. [PMID: 16208181 DOI: 10.1097/01.mnm.0000184944.15532.4a] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
BACKGROUND The reliability of solid phase gastric emptying measurements by scintigraphy requires a marker that remains within the solid component of the test meal, and which is not degraded by the gastric juice throughout the scintigraphic procedure. In Europe, foods are most often labelled with 99mTc rhenium sulfide macrocolloid (RSMC) but this solid phase marker was withdrawn from the market in January 2004. OBJECTIVE To test other potential solid phase markers and to compare them to the reference marker RSMC. These markers were rhenium sulfide nanocolloid (RSNC), tin fluoride colloid (TFC), phytates and two albumins (Alb and AlbC). All were radiolabelled with 99mTc. METHODS After quality control, each 99mTc marker was incorporated into the albumin of one egg. Then, egg white and yolk were mixed together, and a well-cooked omelette was prepared. Aliquots of the omelette were incubated with an acidic solution of pepsin at 37 degrees C which mimicked gastric juice. Unbound radioactivity in the supernatant fraction was measured at various times up to 3 h. RESULTS The radiochemical purity was > 95% for all radiopharmaceuticals. During the in-vitro incubation, the percentage of 99mTc labelled colloids released from the omelette increased continuously: after 3 h, 5% for TFC and RSMC, 8% for phytates, and > 9% for the two albumins and RSNC. CONCLUSION Considering quality controls and release of 99mTc during in-vitro incubation of the omelette, TFC showed the same behaviour as the reference marker RSMC. Thus, TFC seems to be the best candidate to replace RSMC for the radiolabelling of the solid phase of the gastric emptying test meal.
Collapse
|